Tikva Allocell
Developing engineered, allogeneic (donor-derived) cell therapies for adult and pediatric patients with solid tumors
$8MSeries A
Role not disclosedActivity from announced rounds
Developing engineered, allogeneic (donor-derived) cell therapies for adult and pediatric patients with solid tumors